A Phase 3 interventional study of Pioglitazone and metformin and Pioglitazone in Diabetes Mellitus, sponsored by Takeda. Completed at 77 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-29.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 12 that started in 2007, is one of 31 in phase 3, and was the 43rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 30–70 · Healthy volunteers
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 20+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–75
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–70 · Healthy volunteers
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–80
By country, each count listing its studies:
Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 33 · Phase 4 57
First in 2000; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 103 across the 122 interventional studies. Of the 96 that completed or were terminated, 31 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 122 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 14th largest by enrollment of the 85 interventional ones that give a count, is one of 13 that started in 2007, is one of 45 in phase 3, and was the 27th registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
4 of the studies testing pioglitazone in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT05305287The University of Texas Health Science Center at San AntonioQuantifying Hepatic Mitochondrial Fluxes in Humans | 2027-03-31 |
| NCT04501406University of FloridaLow-Dose Pioglitazone in Patients With NASH (AIM 2) | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy of pioglitazone, twice daily (BID), combined with metformin versus pioglitazone taken alone and metformin taken alone in treating Type 2 Diabetes Mellitus.
Pioglitazone hydrochloride (ACTOS®) is a member of a class of oral antidiabetic agents known as thiazolidinediones, which act by reducing insulin resistance. Insulin resistance is a key feature of dysmetabolic syndrome and has been suggested to be the common pathophysiologic basis of both atherosclerosis and type 2 diabetes. Pioglitazone binds to peroxisome proliferator-activated receptors, an effect that is associated with altered transcription of genes capable of influencing carbohydrate and lipid metabolism.
Metformin hydrochloride is an oral antihyperglycemic drug not chemically or pharmacologically related to thiazolidinediones. Metformin is a biguanide, which has been shown to be effective in improving glycemic control in diabetic patients. Metformin inhibits hepatic glucose production, most likely through an inhibition of gluconeogenesis, and its use is associated with an improvement in tissue sensitivity to insulin. In accordance with published algorithms for the use of combination therapy for the treatment of type 2 diabetes, physicians have traditionally combined metformin with other antidiabetic agents.
This study will determine the effect of a fixed-dose combination of metformin with pioglitazone, compared to metformin monotherapy and pioglitazone monotherapy.
Study participation is anticipated to be approximately 6.5 months.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 600 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pioglitazone and metformin
Drug: Pioglitazone
Drug: Metformin
Drug pages: Pioglitazone · Metformin
Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
Also known as: ACTOPLUS MET
Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
Also known as: ACTOS®, AD4833
Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
Also known as: Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet
Percent Change From Baseline in Glycosylated Hemoglobin
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit or week 24 and Glycosylated Hemoglobin collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Fasting Plasma Glucose
The change between the value of Fasting Plasma Glucose collected at final visit or week 24 and Fasting Plasma Glucose collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Fasting Insulin
The change between the Fasting Insulin value collected at final visit or week 24 and Fasting Insulin collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Homeostasis Model Assessment - Insulin Resistance
The change between Homeostasis Model Assessment of Insulin Resistance collected at final visit or week 24 and Homeostasis Model Assessment of Insulin Resistance collected at baseline. Homeostasis Model Assessment measures insulin resistance, calculated by insulin times glucose, divided by a constant (22.5).
Time frame: Baseline and Week 24
Median Percent Change From Baseline in High Sensitivity C-reactive Protein
Measurement for High Sensitivity C-reactive Protein was collected at final visit or week 24 and at baseline. Percent change from baseline is calculated as: \[(Week 24 - baseline levels)/baseline\]\*100
Time frame: Baseline and Week 24
Change From Baseline in Adiponectin
The change between Adiponectin collected at final visit or week 24 and Adiponectin collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Total Cholesterol
The change between Total Cholesterol collected at final visit or week 24 and Total Cholesterol collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Low-Density Lipoprotein Cholesterol
The change between Low-Density Lipoprotein Cholesterol collected at final visit or week 24 and Low-Density Lipoprotein Cholesterol collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in High-Density Lipoprotein Cholesterol
The change between High-Density Lipoprotein Cholesterol collected at final visit or week 24 and High-Density Lipoprotein Cholesterol collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Triglycerides
The change between Triglycerides collected at final visit or week 24 and Triglycerides collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Mean Low Density Lipoprotein Particle Concentration
The change between Low Density Lipoprotein particle concentration collected at final visit or week 24 and Low Density Lipoprotein particle concentration collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Mean Low Density Lipoprotein Particle Size
The change between Low Density Lipoprotein collected at final visit or week 24 and Low Density Lipoprotein collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Large Low Density Lipoprotein (L3) Concentration
The change between Large Low Density Lipoprotein collected at final visit or week 24 and Large Low Density Lipoprotein collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Intermediate-Density Low Density Lipoprotein Concentration
The change between Intermediate-Density Low Density Lipoprotein collected at final visit or week 24 and Intermediate-Density Low Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Change From Baseline in Medium-Small Low Density Lipoprotein Concentration
The change between Medium-Small Low Density Lipoprotein collected at final visit or week 24 and Medium-Small Low Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Change From Baseline in Small Low Density Lipoprotein Concentration
The change between Small Low Density Lipoprotein collected at final visit or week 24 and Small Low Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Change From Baseline in Very Small Low Density Lipoprotein Concentration
The change between Very Small Low Density Lipoprotein collected at final visit or week 24 and Very Small Low Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Change From Baseline in Mean High Density Lipoprotein Particle Concentration
The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Mean High Density Lipoprotein Particle Size
The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Large High Density Lipoprotein (H4+H5) Concentration
The change between Large High Density Lipoprotein collected at final visit or week 24 and Large High Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Change From Baseline in Intermediate-Medium High Density Lipoprotein (H3) Concentration
The change between Intermediate-Medium High Density Lipoprotein collected at final visit or week 24 and Intermediate-Medium High Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Change From Baseline in Small High Density Lipoprotein (H1+H2) Concentration
The change between Small High Density Lipoprotein collected at final visit or week 24 and Small High Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Change From Baseline in Mean Very Low Density Lipoprotein Particle Concentration
The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Mean Very Low Density Lipoprotein Particle Size
The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.
Time frame: Baseline and Week 24
Change From Baseline in Large-Chylomicrons Very Low Density Lipoprotein Concentration
The change between Large-Chylomicrons Very Low Density Lipoprotein collected at final visit or week 24 and Large-Chylomicrons Very Low Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Change From Baseline in Medium-Intermediate Very Low Density Lipoprotein (V3+V4) Concentration
The change between Medium-Intermediate Very Low Density Lipoprotein collected at final visit or week 24 and Medium-Intermediate Very Low Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration
The change between Small Very Low Density Lipoprotein collected at final visit or week 24 and Small Very Low Density Lipoprotein collected at baseline
Time frame: Baseline and Week 24
Participants were enrolled at 134 investigative sites in the United States (including Puerto Rico), Argentina, Chile, Guatemala, Mexico and Peru from 13 June 2007 to 29 August 2008.
| Milestone | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Started | 201 | 189 | 210 |
| Completed | 157 | 125 | 142 |
| Not completed | 44 | 64 | 68 |
The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final visit or week 24 and Glycosylated Hemoglobin collected at baseline.
| percentage of Glycosylated Hemoglobin | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Percent Change From Baseline in Glycosylated Hemoglobin | -1.83 ± 0.122 | -0.96 ± 0.131 | -0.99 ± 0.120 |
The change between the value of Fasting Plasma Glucose collected at final visit or week 24 and Fasting Plasma Glucose collected at baseline.
| mg/dL | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose | -39.9 ± 3.48 | -22.2 ± 3.67 | -24.8 ± 3.42 |
The change between the Fasting Insulin value collected at final visit or week 24 and Fasting Insulin collected at baseline.
| μIU/mL | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Fasting Insulin | -3.91 ± 0.736 | -3.18 ± 0.812 | -0.98 ± 0.722 |
The change between Homeostasis Model Assessment of Insulin Resistance collected at final visit or week 24 and Homeostasis Model Assessment of Insulin Resistance collected at baseline. Homeostasis Model Assessment measures insulin resistance, calculated by insulin times glucose, divided by a constant (22.5).
| percent of insulin resistance | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Homeostasis Model Assessment - Insulin Resistance | -2.704 ± 0.4274 | -2.075 ± 0.4586 | -1.085 ± 0.4123 |
Measurement for High Sensitivity C-reactive Protein was collected at final visit or week 24 and at baseline. Percent change from baseline is calculated as: \[(Week 24 - baseline levels)/baseline\]\*100
| percent | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Median Percent Change From Baseline in High Sensitivity C-reactive Protein | -36.7 ± 4.6719 | -34.0 ± 8.1275 | -26.2 ± 12.5526 |
The change between Adiponectin collected at final visit or week 24 and Adiponectin collected at baseline.
| mcg/ml | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Adiponectin | 7.8 ± 0.55 | 9.2 ± 0.61 | -0.3 ± 0.55 |
The change between Total Cholesterol collected at final visit or week 24 and Total Cholesterol collected at baseline.
| mg/dL | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Total Cholesterol | 1.06 ± 1.183 | 4.79 ± 1.271 | -2.72 ± 1.169 |
The change between Low-Density Lipoprotein Cholesterol collected at final visit or week 24 and Low-Density Lipoprotein Cholesterol collected at baseline.
| mg/dL | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Low-Density Lipoprotein Cholesterol | 1.19 ± 2.015 | 6.08 ± 2.175 | -1.37 ± 1.998 |
The change between High-Density Lipoprotein Cholesterol collected at final visit or week 24 and High-Density Lipoprotein Cholesterol collected at baseline.
| mg/dL | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in High-Density Lipoprotein Cholesterol | 14.20 ± 1.440 | 9.88 ± 1.552 | 6.09 ± 1.426 |
The change between Triglycerides collected at final visit or week 24 and Triglycerides collected at baseline.
| mg/dL | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Triglycerides | -5.95 ± 2.901 | -5.54 ± 3.107 | -1.78 ± 2.871 |
The change between Low Density Lipoprotein particle concentration collected at final visit or week 24 and Low Density Lipoprotein particle concentration collected at baseline.
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Mean Low Density Lipoprotein Particle Concentration | -240.6 ± 23.50 | -217.2 ± 25.40 | -176.4 ± 23.36 |
The change between Low Density Lipoprotein collected at final visit or week 24 and Low Density Lipoprotein collected at baseline.
| nm | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Mean Low Density Lipoprotein Particle Size | 0.55 ± 0.049 | 0.6 ± 0.053 | 0.2 ± 0.049 |
The change between Large Low Density Lipoprotein collected at final visit or week 24 and Large Low Density Lipoprotein collected at baseline.
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Large Low Density Lipoprotein (L3) Concentration | 96.0 ± 12.53 | 115.7 ± 13.52 | 18.4 ± 12.46 |
The change between Intermediate-Density Low Density Lipoprotein collected at final visit or week 24 and Intermediate-Density Low Density Lipoprotein collected at baseline
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Intermediate-Density Low Density Lipoprotein Concentration | -16.3 ± 3.39 | -11.0 ± 3.66 | -17.3 ± 3.37 |
The change between Medium-Small Low Density Lipoprotein collected at final visit or week 24 and Medium-Small Low Density Lipoprotein collected at baseline
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Medium-Small Low Density Lipoprotein Concentration | -63.8 ± 5.95 | -66.0 ± 6.43 | -35.3 ± 5.92 |
The change between Small Low Density Lipoprotein collected at final visit or week 24 and Small Low Density Lipoprotein collected at baseline
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Small Low Density Lipoprotein Concentration | -319.3 ± 28.06 | -321.3 ± 30.34 | -179.0 ± 27.91 |
The change between Very Small Low Density Lipoprotein collected at final visit or week 24 and Very Small Low Density Lipoprotein collected at baseline
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Very Small Low Density Lipoprotein Concentration | -255.5 ± 22.37 | -255.2 ± 24.18 | -143.8 ± 22.25 |
The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.
| μmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Mean High Density Lipoprotein Particle Concentration | 0.28 ± 0.271 | -0.80 ± 0.293 | 0.62 ± 0.269 |
The change between High Density Lipoprotein collected at final visit or week 24 and High Density Lipoprotein collected at baseline.
| nm | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Mean High Density Lipoprotein Particle Size | 0.15 ± 0.021 | 0.19 ± 0.022 | 0.11 ± 0.021 |
The change between Large High Density Lipoprotein collected at final visit or week 24 and Large High Density Lipoprotein collected at baseline
| μmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Large High Density Lipoprotein (H4+H5) Concentration | 0.70 ± 1.80 | 1.02 ± 0.194 | 0.52 ± 0.179 |
The change between Intermediate-Medium High Density Lipoprotein collected at final visit or week 24 and Intermediate-Medium High Density Lipoprotein collected at baseline
| μmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Intermediate-Medium High Density Lipoprotein (H3) Concentration | 1.34 ± 0.285 | 1.62 ± 0.308 | -0.09 ± 0.283 |
The change between Small High Density Lipoprotein collected at final visit or week 24 and Small High Density Lipoprotein collected at baseline
| μmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Small High Density Lipoprotein (H1+H2) Concentration | -1.78 ± 0.349 | -3.41 ± 0.377 | 0.19 ± 0.347 |
The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Mean Very Low Density Lipoprotein Particle Concentration | -2.78 ± 2.204 | 0.98 ± 2.381 | -11.30 ± 2.191 |
The change between Very Low Density Lipoprotein collected at final visit or week 24 and Very Low Density Lipoprotein collected at baseline.
| nm | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Mean Very Low Density Lipoprotein Particle Size | -2.64 ± 0.616 | -3.79 ± 0.666 | -0.20 ± 0.612 |
The change between Large-Chylomicrons Very Low Density Lipoprotein collected at final visit or week 24 and Large-Chylomicrons Very Low Density Lipoprotein collected at baseline
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Large-Chylomicrons Very Low Density Lipoprotein Concentration | -1.71 ± 0.351 | -1.97 ± 0.379 | -1.96 ± 0.349 |
The change between Medium-Intermediate Very Low Density Lipoprotein collected at final visit or week 24 and Medium-Intermediate Very Low Density Lipoprotein collected at baseline
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Medium-Intermediate Very Low Density Lipoprotein (V3+V4) Concentration | -4.07 ± 1.434 | -3.01 ± 1.550 | -6.48 ± 1.426 |
The change between Small Very Low Density Lipoprotein collected at final visit or week 24 and Small Very Low Density Lipoprotein collected at baseline
| nmol/L | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Change From Baseline in Small Very Low Density Lipoprotein (V1+V2) Concentration | 3.05 ± 1.249 | 5.9 ± 1.350 | -2.86 ± 1.239 |
Collected over Adverse events were summarized by onset date occurring on or after the first dose of double-blind study medication and on or prior to 14 days after the permanent discontinuation of the double-blind study medication.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pioglitazone 15 mg/Metformin 850 mg BID | — | 2/201 (1%) | 84/201 (41.8%) |
| Pioglitazone 15 mg BID | — | 3/190 (1.6%) | 61/190 (32.1%) |
| Metformin 850 mg BID | — | 5/209 (2.4%) | 95/209 (45.5%) |
| Event | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/201 | 1/190 | 0/209 |
| HyperglycemiaMetabolism and nutrition disorders | 0/201 | 1/190 | 0/209 |
| EndometriosisReproductive system and breast disorders | 0/201 | 1/190 | 0/209 |
| Diverticulum intestinalGastrointestinal disorders | 1/201 | 0/190 | 0/209 |
| HypoglycemiaMetabolism and nutrition disorders | 1/201 | 0/190 | 0/209 |
| LeukocytosisBlood and lymphatic system disorders | 0/201 | 0/190 | 1/209 |
| Cholecystitis chronicHepatobiliary disorders | 0/201 | 0/190 | 1/209 |
| CellulitisInfections and infestations | 0/201 | 0/190 | 1/209 |
| DiverticulitisInfections and infestations | 0/201 | 0/190 | 1/209 |
| FallInjury, poisoning and procedural complications | 0/201 | 0/190 | 1/209 |
| Event | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 18/201 | 5/190 | 32/209 |
| HeadacheNervous system disorders | 11/201 | 5/190 | 10/209 |
| Urinary tract infectionInfections and infestations | 6/201 | 5/190 | 9/209 |
| Oedema PeripheralGeneral disorders | 6/201 | 8/190 | 3/209 |
| Back painMusculoskeletal and connective tissue disorders | 4/201 | 8/190 | 6/209 |
| PharyngitisInfections and infestations | 8/201 | 5/190 | 7/209 |
| NasopharyngitisInfections and infestations | 8/201 | 3/190 | 5/209 |
| BronchitisInfections and infestations | 5/201 | 7/190 | 3/209 |
| Glycosylated haemoglobinInvestigations | 2/201 | 7/190 | 7/209 |
| Abdominal painGastrointestinal disorders | 4/201 | 3/190 | 7/209 |
| Age Continuous(years) | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID | Total |
|---|---|---|---|---|
| Mean | 54.7 ± 12.23 | 54.0 ± 12.08 | 53.7 ± 12.00 | 54.1 ± 12.09 |
| Sex: Female, Male(Participants) | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID | Total |
|---|---|---|---|---|
| Female | 111 | 123 | 112 | 346 |
| Male | 90 | 66 | 98 | 254 |
| Race/Ethnicity, Customized(participants) | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 6 | 6 | 14 |
| Asian | 3 | 5 | 5 | 13 |
| Black or African American | 12 | 13 | 14 | 39 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| White | 123 | 109 | 124 | 356 |
| Multiracial | 61 | 56 | 61 | 178 |
| Body Mass Index(kg/m²) | Pioglitazone 15 mg/Metformin 850 mg BID | Pioglitazone 15 mg BID | Metformin 850 mg BID | Total |
|---|---|---|---|---|
| Mean | 30.84 ± 5.74 | 31.18 ± 5.50 | 30.83 ± 5.66 | 30.94 ± 5.63 |
The record gives a start of Jun 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pioglitazone · Metformin